Mode
Text Size
Log in / Sign up
N/A Completed N=150 Randomized Double-blind Treatment

Clinical Evaluation of Approved and Investigational Contact Lenses

Visual Disorder
Source: ClinicalTrials.gov NCT02669095 ↗
Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Jun 2017
Primary outcomePrimary: Acceptable Lens Fitting — 1; 0.99 Proportion of eyes

Summary

This study is a multi-site, 5-visit dispensing, bilateral double-arm parallel group design, double-masked clinical trial using an investigational contact lens and a marketed contact lens. The objective is to evaluate comfort of the contact lenses when worn on a daily wear modality.

Outcome Measures

OutcomeResultp-value
PRIMARY
Acceptable Lens Fitting
1; 0.99 —
PRIMARY
Overall Comfort
71.75; 56.68; 70.58; 54.69; 68.75; 53.43 —

Eligibility Criteria

Inclusion Criteria

  • The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  • The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  • The subject must be between 18 to 40 years of age at the time of consent.
  • The subject's vertexed spherical equivalent distance refraction must be in the range of +8.00 to -12.00 in each eye.
  • Subject wears habitual contact lenses a minimum of 4 days per week, eight hours per day.
  • The subject must have best corrected visual acuity of 20/30 or better in each eye.
  • The subject must be a habitual frequent replacement daily wear spherical silicone hydrogel soft contact lens wearer in both eyes.
  • The subject must be able to wear contact lenses for a minimum of 8 hours each day during the study.
  • The subject must have normal eyes (i.e., no ocular medications or infections of any type).

Exclusion Criteria

  • Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  • Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  • Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
  • Any known sensitive/allergic to Ingredients of OPTI-FREE® PureMoist® solution.
  • Entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or moderate or above corneal distortion.
  • Any previous, or planned, ocular or interocular surgery (e.g., radial keratotomy, photorefractive keratectomy (PRK), laser-assisted in situ keratomileusis (LASIK), etc.).
  • Any grade 3 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
  • Any ocular infection.
  • Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  • Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02669095). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search